Eosinophilia in Hodgkin’s Disease: A Role for Interleukin 5

Biagio, Elizabeth Di; Sánchez‐Borges, Mario; Desenne, Jean J.; Suárez-Chacón, Raúl; Somoza, Rosa; Acquatella, G

doi:10.1159/000237294

Cited by 31 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this respect, it should be noted that all cell lines used in this study were obtained from patients suffering from severe erythoderma. It has been proposed that in Hodgkin disease IL-5 is a key mediator of eosinophilia, 13 and studies are now in progress to elucidate whether Stat3 is also involved in IL-5 production in Hodgkin disease and other lymphomas.…”

Section: Discussionmentioning

confidence: 99%

“…In this regard, interleukin-5 (IL-5) is the predominant regulator of eosinophilia 12 and has been shown to play an important role in the development of eosinophilia in Hodgkin disease. 13 Likewise, cytokines such as IL-4, IL-10, and IL-13 stimulate antibody production and hence favor humoral immune responses at the expense of cellular immune responses that are needed to eliminate the tumor. 12 Signal transducer and activator of transcription (Stat) proteins compose a family of transcription factors activated in response to most cytokines and growth factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3

Nielsen

Nissen

Gerwien

et al. 2002

Blood

View full text Add to dashboard Cite

Mycosis fungoides is a low-grade cutanous T-cell lymphoma (CTCL) of unknown etiology. In advanced stages of CTCL, a shift in cytokine profile from T H 1 to T H 2 is observed, which coincides with eosinophilia, high levels of immunoglobulin E, and increased susceptibility to bacterial infections. It is, however, unknown why T H 2 cytokines predominate in advanced CTCL, and the cellular source of these cytokines also remains to be identified. In several leukemias and lymphomas, constitutively activated signal transducer and activator of transcription (Stat) signaling pathways have been detected. In a previous study, constitutive activation of Stat3 was found in tumor cells isolated from affected skin and blood from CTCL patients. Here, it is shown that CTCL tumor cell lines, but not nonmalignant cell lines, spontaneously produce interleukin-5 (IL-5), IL-6, and IL-13. Transfection of tumor cells with dominantnegative Stat3 almost completely blocks IL-5 production and strongly inhibits IL-13 production, whereas IL-6 production is unaffected. Thus, the data show that malignant CTCL cells themselves might contribute to the change in cytokine pattern accompanying progression of CTCL. In conclusion, constitutively activated Stat3 is found to mediate a spontaneous IL-5 production and regulate IL-13 production in CTCL cell lines, pointing toward a new role of Stat3 in malignant transformation. (Blood. 2002;99:973-977)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3

Nielsen

Nissen

Gerwien

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

“…Malignancy-associated eosinophilia is a well-recognized but unusual symptom in different malignancies, in which the pathogenesis seems to be related to an increased production and secretion of cytokines and growth factors, especially interleukin(IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF); either by the malignant cells themselves or by reactive CD4 positive T-helper type 2 lymphocytes [2][3][4]7,8]. Hematological malignancies presenting with eosinophilia include classical myeloproliferative disorders (i.e.…”

Section: Discussionmentioning

confidence: 99%

“…chronic myeloid leukemia, polycythemia vera, myelofibrosis) or neoplasms with distinct genetic abnormalities (i.e. mutations in PDGFRA, PDGFRB or FGFR1 genes) as well as Hodgkin lymphoma [4,8]. In contrast, only a few cases of eosinophilia were reported in acute lymphoblastic leukemia or non-Hodgkin lymphoma [4].…”

Section: Discussionmentioning

confidence: 99%

Eosinophilia as a presenting symptom of the metastatic lung adenocarcinoma with an unknown primary localization

Machaczka¹,

Hubert

Kasina

et al. 2011

Open Medicine

View full text Add to dashboard Cite

AbstractApparent hematological symptoms rarely dominate the clinical picture of an underlying non-hematological malignancy. Malignancy-associated eosinophilia can result from clonal or non-clonal proliferation of eosinophils. Here, we report the case of a 59-year-old man with metastatic adenocarcinoma of the lung with an unknown primary tumor site, which presented as hypereosinophilia, anemia, lymphadenopathy, weight loss, and malaise. Bone marrow biopsy disclosed metastatic adenocarcinoma positive in immunohistochemistry for cytokeratin 7. Further assessment of specimens obtained from the bronchoalveolar lavage and biopsy of the mediastinal lymph nodes confirmed the diagnosis of the metastatic lung cancer, although the primary tumor site remained undiscovered. This case underlines that eosinophilia may represent a rare primary manifestation of an undetected malignancy, and it is thus important to consider this as part of the differential diagnosis in patients presenting with unexplained eosinophilia.

show abstract

“…18 Patients with HL are reported to have high eosinophil counts and serum IgE compared to age-and sexmatched controls. 24 Fludarabine and cladribine, [25][26][27] the drugs used in the treatment of CLL, can also cause eosinophilia.…”

Section: Hematological Paraneoplastic Phenomenamentioning

confidence: 99%

Paraneoplastic Manifestations of Lymphoproliferative Neoplasms

2016

Lymphoma and Chronic Lymphocytic Leukemias

View full text Add to dashboard Cite

Paraneoplastic syndromes, although rare, have been associated with lymphoproliferative disorders. Hodgkin's lymphoma (HL) is the most common lymphoid neoplasm known to cause paraneoplastic syndromes. These syndromes can often be the earliest manifestation of the underlying malignancy, and treating the underlying lymphoma can cure the paraneoplastic disease. Paraneoplastic diseases reported in lymphoid malignancies can be broadly classified into hematological, neurological, and dermatological syndromes based on the organ systems that are predominantly involved. In addition, renal and hepatobiliary involvement has also been reported. The pathogenesis of the hematological paraneoplastic conditions primarily involves the production of autoantibodies by the neoplastic lymphocytes, which then subsequently leads to cytopenias. Cytoses are a result of cytokine produced by the neoplasms. The administration of corticosteroids along with chemotherapy for the underlying malignancy is the treatment of choice. Neurological paraneoplastic phenomena have been reported in both HL and non-Hodgkin's lymphoma (NHL). They are thought to be secondary to an immune-related process that is triggered by the underlying process. Both the central and the peripheral nervous systems can be affected. Often, treatment of the underlying malignancy with chemotherapy can result in reversal of the paraneoplastic syndrome. In peripheral neuropathies, muscle relaxants and analgesics are often used for symptomatic relief. Dermatological manifestations, pemphigus vulgaris in particular, often precedes the malignancy. Renal and hepatobiliary manifestations, although rare, are also associated with lymphomas.

show abstract

Eosinophilia in Hodgkin’s Disease: A Role for Interleukin 5

Cited by 31 publications

References 13 publications

Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3

Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3

Eosinophilia as a presenting symptom of the metastatic lung adenocarcinoma with an unknown primary localization

Paraneoplastic Manifestations of Lymphoproliferative Neoplasms

Contact Info

Product

Resources

About